Shuqi Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuqi Liu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Guowei Xu
Traditional Chinese Veterinary Technology Innovation Center of Gansu Province, Key Laboratory of Veterinary Pharmaceutical Development of Ministry of Agriculture and Rural Affairs of China, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Sciences, Lanzhou 730050, China
2 shared publications - Jianxi Li
Engineering and Technology Research Center of Traditional Chinese Veterinary Medicine of Gansu Province, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou 730050, China
2 shared publications - Jingyan Zhang
Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou 730050, China
2 shared publications - Junyan Wang
Traditional Chinese Veterinary Technology Innovation Center of Gansu Province, Key Laboratory of Veterinary Pharmaceutical Development of Ministry of Agriculture and Rural Affairs of China, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Sciences, Lanzhou 730050, China
2 shared publications - Kang Zhang
Traditional Chinese Veterinary Technology Innovation Center of Gansu Province, Key Laboratory of Veterinary Pharmaceutical Development of Ministry of Agriculture and Rural Affairs of China, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Sciences, Lanzhou 730050, China
2 shared publications - Lei Wang
Technology Innovation Center of Traditional Chinese Veterinary Medicine of Gansu Province, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China
2 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13 (10) , 1002
Mechanistic Investigation of Cryptotanshinone and Curcumin Combination in Attenuating BVDV-1-Induced Injury in Bovine Ovarian Granulosa Cells
Bovine viral diarrhea virus (BVDV) is a widespread pathogen causing significant economic losses in cattle. There is an urgent need for drugs to treat BVDV-induced reproductive dysfunction. This study investigated the mechanisms and targets of the cryptotanshinone–curcumin (CRY-CUR) combination against BVDV-1. Overlapping targets of CRY, CUR, and BVDV were screened using TCMSP, ChEMBL, and GeneCards databases. A Venn diagram was generated, followed by GO and KEGG enrichment analyses via DAVID. A PPI network was constructed using Cytoscape, and molecular docking was performed with AutoDock. Anti-BVDV-1 activity was verified in bovine ovarian granulosa cells (BOGCs) using RT-qPCR and immunofluorescence. A total of 108 overlapping targets were identified, with four core targets (STAT3, TNF, BCL-2, and EGFR) selected. Molecular docking showed strong binding affinities. Enrichment analysis indicated involvement in calcium ion binding, apoptosis, and TNF/NF-κB pathways. In vitro, the CRY-CUR combination suppressed BVDV-1 replication and reversed abnormal mRNA expression of the core targets. The CRY-CUR combination may inhibit BVDV-1 replication, potentially through modulation of BVDV-1-related targets such as STAT3, TNF, BCL-2, and EGFR and their associated signaling pathways.
- 23 September 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13 (10) , 1002
Open AccessMechanistic Investigation of Cryptotanshinone and Curcumin Combination in Attenuating BVDV-1-Induced Injury in Bovine Ovarian Granulosa Cells
Bovine viral diarrhea virus (BVDV) is a widespread pathogen causing significant economic losses in cattle. There is an urgent need for drugs to treat BVDV-induced reproductive dysfunction. This study investigated the mechanisms and targets of the cryptotanshinone–curcumin (CRY-CUR) combination against BVDV-1. Overlapping targets of CRY, CUR, and BVDV were screened using TCMSP, ChEMBL, and GeneCards databases. A Venn diagram was generated, followed by GO and KEGG enrichment analyses via DAVID. A PPI network was constructed using Cytoscape, and molecular docking was performed with AutoDock. Anti-BVDV-1 activity was verified in bovine ovarian granulosa cells (BOGCs) using RT-qPCR and immunofluorescence. A total of 108 overlapping targets were identified, with four core targets (STAT3, TNF, BCL-2, and EGFR) selected. Molecular docking showed strong binding affinities. Enrichment analysis indicated involvement in calcium ion binding, apoptosis, and TNF/NF-κB pathways. In vitro, the CRY-CUR combination suppressed BVDV-1 replication and reversed abnormal mRNA expression of the core targets. The CRY-CUR combination may inhibit BVDV-1 replication, potentially through modulation of BVDV-1-related targets such as STAT3, TNF, BCL-2, and EGFR and their associated signaling pathways.
- Open Access
- 3 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1279
Cordycepin Alleviates Acute Lung Injury by Targeting TAK1 to Inhibit MAPK and NF-κB Signaling Pathways
Acute lung injury (ALI) is a common clinical acute respiratory disorder driven primarily by a diffuse pulmonary inflammatory response. Cordycepin (COR) is a bioactive metabolite extracted from the fungus Cordyceps militaris, which possesses antioxidant and anti-inflammatory properties. However, its underlying molecular mechanism remains to be elucidated. This study evaluated the therapeutic effect of COR on ALI and the underlying molecular mechanisms. MH-S cells were primed with lipopolysaccharide (LPS) at 1 µg/mL for 24 h and then treated with varying doses of COR for an additional 24 h. WB and RT-qPCR analyses showed that COR inhibited the phosphorylation of TGF-β-activated kinase 1 (TAK1) as well as the key kinases in the MAPK and NF-κB pathways in LPS-induced MH-S cells, as evidenced by decreased TAK1, p38, JNK, IκB-α and P65 expression levels, as well as decreased TNF-α, IL-6, IL-1β, MAP3K7, MAPK8 and MAPK14 relative expression. Six-week-old BALB/c mice were intranasally instilled with LPS at 3 mg/kg, followed 24 h later by oral gavage administration of various concentrations of COR. The results showed that COR can effectively suppress the progression of pulmonary tissue injury; similarly, the expression levels of key proteins and inflammatory factors in the TAK1-MAPK and NF-κB signaling pathways were downregulated. In summary, COR exerts a therapeutic effect on ALI by directly targeting TAK1 to inhibit the activation of the MAPK and NF-κB signaling pathways and concurrently suppressing key inflammatory cytokines.
- 3 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1279
Open AccessCordycepin Alleviates Acute Lung Injury by Targeting TAK1 to Inhibit MAPK and NF-κB Signaling Pathways
Acute lung injury (ALI) is a common clinical acute respiratory disorder driven primarily by a diffuse pulmonary inflammatory response. Cordycepin (COR) is a bioactive metabolite extracted from the fungus Cordyceps militaris, which possesses antioxidant and anti-inflammatory properties. However, its underlying molecular mechanism remains to be elucidated. This study evaluated the therapeutic effect of COR on ALI and the underlying molecular mechanisms. MH-S cells were primed with lipopolysaccharide (LPS) at 1 µg/mL for 24 h and then treated with varying doses of COR for an additional 24 h. WB and RT-qPCR analyses showed that COR inhibited the phosphorylation of TGF-β-activated kinase 1 (TAK1) as well as the key kinases in the MAPK and NF-κB pathways in LPS-induced MH-S cells, as evidenced by decreased TAK1, p38, JNK, IκB-α and P65 expression levels, as well as decreased TNF-α, IL-6, IL-1β, MAP3K7, MAPK8 and MAPK14 relative expression. Six-week-old BALB/c mice were intranasally instilled with LPS at 3 mg/kg, followed 24 h later by oral gavage administration of various concentrations of COR. The results showed that COR can effectively suppress the progression of pulmonary tissue injury; similarly, the expression levels of key proteins and inflammatory factors in the TAK1-MAPK and NF-κB signaling pathways were downregulated. In summary, COR exerts a therapeutic effect on ALI by directly targeting TAK1 to inhibit the activation of the MAPK and NF-κB signaling pathways and concurrently suppressing key inflammatory cytokines.